newsfilter
← Latest News
GlobeNewswire·

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

CDT
  • CDT Equity Inc. announced a partnership with QIMA Life Sciences to explore CDT assets for autoimmune skin diseases.
  • CDT will leverage QIMA's access to human skin from healthy donors and patients to generate clinically relevant data.
  • Initial studies will focus on tapinarof (VTAMA®), a drug approved for plaque psoriasis and atopic dermatitis.
  • CDT aims to develop a second-generation tapinarof product with increased efficacy using novel combinations of solid form and method-of-use patents.
  • The company plans to investigate tapinarof combinations for vitiligo, a condition affecting 0.5%–2.0% of the global population.
  • The global vitiligo drug market was valued at US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 2030.
  • Current vitiligo treatments often lack tolerability, particularly for pediatric patients, creating an unmet need for new therapies.
  • QIMA Life Sciences specializes in cellular and molecular pharmacology using AI-driven image analysis to accelerate drug development.
  • CDT Equity Inc. is a data-driven biopharmaceutical company focused on advancing therapeutic assets through scientific innovation.
  • The press release includes a cautionary statement regarding forward-looking statements and associated risks.